Somatostatin receptor type 2 (SSTR2) is ubiquitously expressed in up to 100% of meningiomas and can be addressed by radiolabeled SSTR2 ligands such as [68Ga]Gallium-DOTA-TATE, [68Ga]Gallium-DOTA-TOC, and most recently [18F]SiTATE [18, 19]. This evidence concerns the gene SSTR2 and meningioma.